Form 4: ICAD INC Director Rakesh Patel Acquires Stock Options in Lieu of Cash Fees

Director Rakesh Patel acquired 24,194 stock options in ICAD INC on August 15, 2024, in lieu of quarterly cash director fees.

Summary

• On August 15, 2024, Rakesh Patel, a director of ICAD INC, acquired 24,194 stock options.
• These options were granted in lieu of quarterly cash director fees.
• The exercise price of the options is $1.49.
• The options are immediately exercisable and expire on August 15, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard director compensation practices that align interests with shareholders.

Positives

• The acquisition of stock options by a director aligns their interests with those of the shareholders.
• Granting options in lieu of cash preserves the company's cash reserves.

Industry Context

This type of equity compensation is common for directors, aligning their interests with shareholders and conserving company cash.

Comparison to Industry Standards

• Granting stock options to directors is a common practice in the industry to align their interests with those of shareholders.
• The specific number of options and exercise price would need to be compared to similar companies in the medical technology sector to assess if it is within the typical range.
• Companies like Varex Imaging and Hologic also use stock options as part of their director compensation packages.

Stakeholder Impact

• The granting of stock options to a director can be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.
• It has a neutral impact on employees, customers, suppliers, and creditors.

Key Dates